Epithelial-mesenchymal transition (EMT) plays a pivotal role in cancer invasion and metastasis, and transforming growth factor (TGF)-β signaling is a potent inducer of EMT. However, the clinical significance of the correlation between EMT marker expression and TGF-β signaling in hepatocellular carcinoma (HCC) patients remains unknown. In this study, immunohistochemistry was used to analyze the expression of EMT markers and phospho-Smad2 nuclear positivity, and their association with clinicopathological features in 150 HCC patients. E-cadherin high /vimentin low and E-cadherin low /vimentin high expression profiles were determined in 55 (36.7%) and 21 (14.0%) patients, respectively. The E-cadherin low /vimentin high expression profile was significantly correlated with poor tumor differentiation (P<0.001), vascular invasion (P=0.007) and extrahepatic recurrence following curative surgery (P=0.026). Furthermore, the E-cadherin low /vimentin high expression profile was significantly correlated with shorter disease-free survival compared to E-cadherin high /vimentin low (P=0.002). Forty-one patients (27.3%) were demonstrated to have high phospho-Smad2 nuclear positivity, which was significantly correlated with the E-cadherin low /vimentin high expression profile (P<0.001). In conclusion, this study suggests that EMT expression profiles are useful prognostic markers for disease-free survival in HCC patients, and that the E-cadherin low /vimentin high expression profile is closely associated with high-grade malignant behavior such as tumoral vascular invasion and metastasis in HCC. Additionally, TGF-β-mediated EMT may play an important role in the aggressiveness of HCC.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most prevalent and third most fatal type of cancer worldwide, and is currently diagnosed in over half a million people each year globally (1) . Surgical resection is often performed as the most effective treatment for early-stage HCC. However, the 5-year risk of recurrence of HCC following resection is as high as 50-70%, due to its high invasiveness and the frequent occurrence of intra-and /or extrahepatic metastases.
Epithelial-mesenchymal transition (EMT) has been shown to be a pivotal mechanism contributing to cancer invasion and metastasis, as epithelial cells lose their polarity and acquire the migratory properties of mesenchymal cells. The characteristic changes during EMT include the downregulation of epithelial markers, such as E-cadherin and the upregulation of mesenchymal markers such as vimentin (2) . A correlation between the expression profiles of EMT and EMT inducers, and tumor recurrence and distant metastasis, has been demonstrated in certain types of cancer, including breast and colon cancer (3, 4) . With regards to HCC, several EMT-related transcription factors such as Snail, Twist and Zinc finger E-box binding protein 1 (ZEB1) have been demonstrated to be involved in the process of EMT, and thus associated with a poor prognosis (5, 6) .
Transforming growth factor (TGF)-β signaling plays a central role in tumorigenesis and tumor progression by regulating many critical cellular processes, including cell proliferation, apoptosis and EMT. TGF-β binds to type I and type II serine/threonine kinase receptors, resulting in the translocation of phosphorylated Smad proteins (phospho-Smad2 and 3) into the nucleus where they regulate the expression of various target genes (7) . A previous study using HCC cell lines demonstrated that TGF-β signaling triggered EMT, which was characterized by E-cadherin low /vimentin high expression in vitro (8) . However, the existence of a clinical association between the expression profiles of EMT markers and TGF-β signaling, and its significance in HCC patients remains to be elucidated.
In the present study, we investigated the expression of the EMT markers E-cadherin and vimentin (epithelial and mesenchymal markers, respectively) and phospho-Smad2 by immunohistochemical (IHC) analyses. The clinical significance of the expression profiles and TGF-β signaling in HCC patients were further assessed.
Materials and methods
Patients and treatment. One-hundred and fifty primary HCC samples amongst 235 consecutive patients who underwent curative hepatic resection in the Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, between 2004 and 2007, were analyzed in this study. None of the patients had received any pre-operative anticancer treatment. The pathologic diagnoses and clinicopathological features were established based on the general guideline for primary liver cancer as defined by the Liver Cancer Study Group of Japan (9,10) and the American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC) staging system (11) . The median follow-up duration following surgery was 44 months. Informed consent was obtained from all patients and the study was approved by the Human Ethics Review Committee of the Graduate School of Medicine, Kumamoto University (Kumamoto, Japan).
Immunohistochemistry and scoring. The sample processing and IHC procedures were performed as described in a previous study by Okabe et al (12) . Endogenous peroxidase activity was blocked using 3% hydrogen peroxide and the sections were incubated with diluted antibodies. A subsequent reaction was performed with a biotin-free horseradish peroxidase enzyme-labeled polymer from the Envision Plus detection system (Dako Japan Inc., Tokyo, Japan). Phospho-Smad2 antibody binding was detected using the Vectastain ABC Elite avidin/biotin/peroxidase kit (Vector Laboratories Inc., Burlingame, CA, USA). A positive reaction was visualized with the addition of diaminobenzidine solution, which was followed by counterstaining with Mayer's hematoxylin solution. Primary antibodies for E-cadherin (1:100 dilution; Japan BD, Tokyo, Japan), vimentin (1:50 dilution; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), and phospho-Smad2 (1:100 dilution; Cell Signaling Technology Japan, Tokyo, Japan) were used for this study. All IHC staining results were independently scored by two pathologists. The membranous E-cadherin and cytoplasmic vimentin expression was interpreted according to the guidelines published in a previous study by Yang et al (13) . For membranous E-cadherin, cytoplasmic vimentin and phospho-Smad2-positive nuclei, the results were graded into categories from 0-3+ as follows: 0, no staining; 1+, 1-25% staining; 2+, 26-50% staining and 3+, >50% of the specimen was stained. For membranous E-cadherin and phospho-Smad2-positive nuclei, the 2+ and 3+ samples were defined as positive IHC results. For cytoplasmic vimentin, the 3+ specimens were defined as positive IHC results.
Statistical analyses.
All experiments were performed in triplicate and the data shown are representative of the results. Categorical variables were compared using a χ 2 test. Overall survival and disease-free survival were calculated using the Kaplan-Meier method and compared using a log-rank test. Statistical analyses were performed as indicated with a statistical analysis software program (Excel Statistics, Social Survey Research Information Co. Ltd., Tokyo, Japan). P<0.05 was considered to indicate a statistically significant difference.
Results

EMT expression profile in HCC patients and its correlation
with TGF-β signaling. E-cadherin was mainly expressed in the tumor cell membrane, whereas vimentin was expressed in the tumor cytoplasm ( Fig. 1 ). Among the 150 HCC patients, low and high E-cadherin expression levels were found in 92 (61.3%) and 58 (38.7%) patients, respectively. On the other hand, low and high vimentin expression levels were found in 126 (84.0%) and 24 (16.0%) patients, respectively. The EMT expression profiles in 150 HCC patients are summarized in Fig. 2 . In patients with HCC, a majority (47.3%) exhibited an E-cadherin low /vimentin low expression profile, whereas a minority (2%) had an E-cadherin high /vimentin high expression profile. Of the 150 HCC patients, 55 (36.7%) were revealed to have an E-cadherin high /vimentin low expression profile (low ability of EMT), whereas 21 (14.0%) were diagnosed with an E-cadherin low /vimentin high profile (high ability of EMT). TGF-β signaling plays a central role in EMT; treatment of HCC cell lines with TGF-β1 induced the E-cadherin low / vimentin high expression profile indicative of high ability of EMT (8) . Therefore, we assessed the clinical relevance of TGF-β signaling in patients with HCC by IHC analysis of phospho-Smad2; 41 (27.3%) of 150 patients showed high phospho-Smad2 nuclear positivity. To investigate the clinical association between the EMT marker profiles and TGF-β signaling, phospho-Smad2 nuclear positivity was compared between the subgroups with an E-cadherin high /vimentin low (low ability of EMT) or E-cadherin low /vimentin high (high ability of EMT) expression profile. The E-cadherin low / vimentin high expression profile was significantly correlated with high phospho-Smad2 nuclear positivity, compared with the E-cadherin high /vimentin low expression profile (P<0.001; Table I ). These findings suggest that TGF-β signaling is closely associated with the EMT expression profile in HCC patients. Table I) . The E-cadherin low /vimentin high expression profile was significantly correlated with poor tumor differentiation (P<0.001), vascular invasion (P=0.007) and extrahepatic recurrence following curative surgery (P=0.026), compared with the E-cadherin high /vimentin low expression profile. Cancer cells invading the portal vein, which is a distinctive characteristic of HCC, were negative for E-cadherin and positive for vimentin expression (Fig. 3) . These findings suggest that EMT plays an important role in the invasive and metastatic phenotype of human HCC. In addition, we compared the clinicopathological features between patients with low and high phospho-Smad2 nuclear positivity. High phospho-Smad2 nuclear positivity was significantly correlated with the E-cadherin low /vimentin high expression profile (P<0.001). Although high phospho-Smad2 nuclear positivity was positively correlated with large tumor size (P=0.154), multiple tumors (P=0.110) and poor tumor differentiation (P=0.154) compared with low phospho-Smad2 nuclear positivity, the correlations were not statistically significant (Table II) .
E-cadherin low /vimentin high expression profile is associated with tumor invasion and metastasis in HCC patients. The correlation between the E-cadherin low /vimentin high expression profile and clinical invasiveness in HCC was further investigated by comparing the clinicopathological features between patients with E-cadherin low /vimentin high (high ability of EMT) and E-cadherin high /vimentin low (low ability of EMT) expression profiles (
E-cadherin low /vimentin high expression profile is associated with poor disease-free survival in HCC patients. We investigated the prognostic implications of the E-cadherin low /vimentinhigh expression profile in HCC patients. The E-cadherin low / vimentin high expression profile was significantly correlated with
shorter disease-free survival, compared to the E-cadherin high / vimentin low expression profile (P= 0.002; Fig. 4A ). E-cadherin low / vimentin high was also correlated with poorer overall survival than E-cadherin high /vimentin low ; however, the difference was not statistically significant (P=0.129; Fig. 4B ).
Discussion
This study demonstrated that a high ability of EMT (an E-cadherin low /vimentin high expression profile) was closely A B (14, 15) . Cancer cell invasion of the portal vein is a clinically defined characteristic of HCC. Notably, the cancer cells invading the portal vein revealed a high ability of EMT, reflected in their E-cadherin low /vimentin high expression profile (Fig. 3) .
In contrast, analysis of another cohort of 123 HCC samples revealed no correlation between either Snail/Twist overexpression or E-cadherin downregulation and vascular invasion (5) .
This study suggests that the loss of E-cadherin followed by the overexpression of vimentin may play a pivotal role in the invasive and metastatic phenotype and in the process of EMT, leading to unfavorable outcomes in patients with HCC. TGF-β signaling is known to be a potent EMT inducer and is strongly associated with cancer progression; EMT primes cancer cells for pulmonary metastasis and metastatic colonization in the bones (16, 17) . In the present study, activated TGF-β signaling indicated by phospho-Smad2 nuclear positivity was found in 27.3% (41/150) of HCC patients. Furthermore, phospho-Smad2 nuclear positivity was correlated with a high ability of EMT (E-cadherin low /vimentin high ) in HCC patients. It has been demonstrated that TGF-β1 is overexpressed in tumor cells, which is associated with a poor prognosis in patients with HCC (18, 19) . These findings suggest that the activation of TGF-β signaling is closely associated with EMT expression profiles in HCC patients. However, TGF-β signaling was not activated in one-third of patients with an E-cadherin low / vimentin high expression profile. Although the precise mechanism of EMT induction in these patients remains unclear, it is possible that several transcription factors (such as Snail, Twist and ZEB1) as well as other molecules are also involved in the process of EMT and are therefore associated with a poor prognosis in HCC (5, 6, (20) (21) (22) (23) (24) (25) (26) (27) . Thus, several mechanisms, including TGF-β signaling, may be involved in the process of EMT in HCC patients.
In conclusion, EMT expression profiles are useful prognostic markers for disease-free survival in HCC patients, and an E-cadherin low /vimentin high expression profile is closely associated with high-grade malignant behavior, such as tumoral vascular invasion and metastasis in HCC. TGF-β-mediated EMT may play a significant role in the aggressiveness of HCC.
